2016年11月30日，江苏恒瑞医药股份有限公司（以下简称“恒瑞”或“本公司”）与日本OncolysBioPharma公司（以下简称“Oncolys”）达成协议，本公司有偿获得Oncolys研发的溶瘤腺病毒产品TelomelysinTM（OBP-301）在中国大陆、香港和澳门特别行政区（以下简称“区域内”）的开发、生产及商业化的独家许可权。
交易金额及付款安排
本次本公司获得Oncolys研发的溶瘤腺病毒产品TelomelysinTM(OBP-301)在中国大陆、香港和澳门特别行政区（以下简称“区域内”）的开发、生产及商业化的独家许可权，交易金额为不超过一亿零两百万美金。包括：
（1）首付款为五十万美元，根据约定于本协议生效后支付；
（2）开发阶段里程碑款最高不超过一千四百五十万美元，销售阶段里程碑款最高不超过八千七百万美元，将根据进度分批支付。
此外，TelomelysinTM(OBP-301)产品销售提成的区间为8%至14%，恒瑞应在销售提成期间按约定比例根据产品的实际销售额支付销售分红。
目前，未看到恒瑞医药在该项目上有在CDE申报。
2019年4月8日，Oncolys BioPharma Inc.和日本中外制药（罗氏控股）就Telomelysin (OBP-301)达成在日本和中国台湾地区的权益合作，首付5.5亿日元。Oncolys BioPharma新发行的8亿日元股票，中外将全部接收。
附原文：
TOKYO, April 8, 2019 — Oncolys BioPharma Inc. (hereafter, “Oncolys”) and Chugai Pharmaceutical Co., Ltd.(hereafter, “Chugai”) announced today the both companies have entered into an agreement that Oncolys will grant an exclusive license, with sublicensing rights, to Chugai concerning the development, manufacturing and marketing in Japan and Taiwan for “Telomelysin (OBP-301)” (hereafter, “Telomelysin”) an oncolytic viral immunotherapy which is currently under development by Oncolys. In addition, licensing agreement that grantsexclusive option rights concerning the worldwide development, manufacturing and marketing of Telomelysin, excluding Japan, Taiwan, China, Hong Kong and Macau to Chugai has also been concluded. Moreover, both companies agreed that Oncolys will newly issue common stock worth approximately 800 million yen, and Chugai will accept all the stocks. The start of this licensing agreement and the payment accompanying the issuance of new shares by third-party allotment are planned on April 24, 2019.
Chugai shall pay 550 million yen as an upfront payment for the exclusive licensing agreement, with sublicensing rights, in Japan and Taiwan. If a certain level of efficacy has been confirmed in the clinical study of Telomelysin, and in case Chugai exercised the exclusive option rights described above, the total value of the licensing agreement which Chugai shall pay to Oncolys will be 50 billion yen or more. In addition, after the launch of Telomelysin, Chugai shall pay to Oncolys, sales royalties according to Chugai’s amount of sales of Telomelysin, apart from the total value of the licensing agreement.
https://www.oncolys.com/en/
更多信息，扫码关注药融数据！
